Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy (Q44634873)

4 December 2017

Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy (English)

1 reference

4 December 2017

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)61689-4

26 March 2024

author name string

Arnon Goldberg

series ordinal

1

1 reference

4 December 2017

Ronit Confino-Cohen

series ordinal

2

1 reference

4 December 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14582821

26 March 2024

publication date

1 October 2003

1 reference

full work available at URL

4 December 2017

https://api.elsevier.com/content/article/PII:S1081120610616894?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S1081-1206(10)61689-4

https://api.elsevier.com/content/article/PII:S1081120610616894?httpAccept=text/plain

26 March 2024

1 reference

DOI

https://api.crossref.org/works/10.1016/S1081-1206(10)61689-4

Annals of Allergy, Asthma & Immunology

26 March 2024

published in

1 reference

4 December 2017

91

1 reference

4 December 2017

4

1 reference

4 December 2017

405-410

1 reference

Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

1 reference

7 January 2021

Dose dependence of Hymenoptera venom immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

The incidence and nature of adverse reactions to injection immunotherapy in bee and wasp venom allergy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Regimens of Hymenoptera venom immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Safety of Hymenoptera venom rush immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Venom immunotherapy in hymenoptera sting allergy. Comparison of rush and conventional hyposensitization and observations during long-term treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

A double-blind study comparing monomethoxy polyethylene glycol-modified honeybee venom and unmodified honeybee venom for immunotherapy. I. Clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Immediate adverse reactions to immunotherapy in allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

The Hymenoptera venom study. III: Safety of venom immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Clinical characteristics of patients with repeated systemic reactions during specific immunotherapy with hymenoptera venoms. A retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Wasp venom immunotherapy induces a shift from IL-4-producing towards interferon-gamma-producing CD4+ and CD8+ T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Immunologic changes associated with allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Allergen-specific production of interferon-gamma by peripheral blood mononuclear cells and CD8 T cells in allergic disease and following immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Relevance of basophil histamine release changes during venom immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Role of interleukin 10 in specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

New developments in the diagnosis and treatment of hymenoptera venom allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Anaphylaxis after hymenoptera stings in three patients with urticaria pigmentosa

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Rush Hymenoptera venom immunotherapy: successful treatment in a patient with systemic mast cell disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961689-4

7 January 2021

Identifiers

DOI

1 reference

release_xfiq2qzrqjepdm4thvf2egooui

4 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xfiq2qzrqjepdm4thvf2egooui

24 November 2022

mapped directly with Wikidata item

1 reference